FDA Approves Genentech’s Evrysdi (risdiplam) for Use in Babies Under Two Months With Spinal Muscular Atrophy (SMA)
– Approval based on interim RAINBOWFISH data which show pre-symptomatic babies treated with Evrysdi for at least one year were able to sit, stand and walk – – Prescribing information updated with FIREFISH data showing the majority of symptomatic babies treated with Evrysdi for at least two years could sit for at least 5 seconds … [Read more…]